Cormorant Asset Management LP Has $36.12 Million Position in enGene Holdings Inc. $ENGN

Cormorant Asset Management LP raised its stake in enGene Holdings Inc. (NASDAQ:ENGN) by 72.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,000,000 shares of the company’s stock after buying an additional 1,676,405 shares during the quarter. enGene comprises approximately 1.7% of Cormorant Asset Management LP’s investment portfolio, making the stock its 12th biggest holding. Cormorant Asset Management LP owned 5.97% of enGene worth $36,120,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Siren L.L.C. acquired a new position in enGene during the fourth quarter worth $30,126,000. Braidwell LP acquired a new position in enGene during the third quarter worth $15,479,000. MPM Bioimpact LLC boosted its holdings in enGene by 247.1% during the fourth quarter. MPM Bioimpact LLC now owns 1,840,898 shares of the company’s stock worth $16,623,000 after purchasing an additional 1,310,599 shares during the last quarter. Polar Capital Holdings Plc acquired a new position in enGene during the fourth quarter worth $10,321,000. Finally, Eventide Asset Management LLC acquired a new position in enGene during the fourth quarter worth $8,578,000. Institutional investors own 64.16% of the company’s stock.

Analyst Upgrades and Downgrades

ENGN has been the subject of several recent research reports. UBS Group reduced their target price on shares of enGene from $9.00 to $2.00 and set a “neutral” rating for the company in a report on Thursday, May 14th. Guggenheim cut shares of enGene from a “buy” rating to a “neutral” rating in a report on Thursday, May 7th. Oppenheimer cut shares of enGene from an “outperform” rating to a “market perform” rating in a report on Friday, May 8th. WBB Securities began coverage on shares of enGene in a report on Monday, April 13th. They set a “buy” rating and a $21.50 target price for the company. Finally, HC Wainwright dropped their price target on shares of enGene from $6.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday. Four analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $12.50.

enGene Stock Performance

NASDAQ ENGN opened at $1.74 on Thursday. The company has a current ratio of 12.57, a quick ratio of 11.75 and a debt-to-equity ratio of 0.10. The firm’s fifty day moving average price is $4.10 and its two-hundred day moving average price is $7.10. enGene Holdings Inc. has a 1 year low of $1.40 and a 1 year high of $12.25. The firm has a market capitalization of $116.56 million, a P/E ratio of -0.80 and a beta of -0.30.

enGene (NASDAQ:ENGN) last posted its quarterly earnings results on Monday, June 15th. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.91. During the same quarter in the prior year, the business earned $0.51 EPS. As a group, research analysts anticipate that enGene Holdings Inc. will post -1.97 EPS for the current year.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.